Related Experiment Video
Updated: May 23, 2026
10:03
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Restoring insulin production for type 1 diabetes
Eva Tudurí1, Jennifer E Bruin, Timothy J Kieffer
1Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Journal of Diabetes
|March 21, 2012
Summary
Restoring insulin production is key for type 1 diabetes treatment. Researchers are exploring cell therapies and gene engineering to overcome limitations of current insulin injections and transplants.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Gene Therapy
Background:
- Current type 1 diabetes treatments like insulin injections and islet transplantation have significant limitations, including dose inaccuracy, long-term complications, donor scarcity, and graft failure.
- These challenges highlight the need for innovative strategies to restore endogenous insulin production in patients.
Purpose of the Study:
- To review and discuss various emerging strategies for restoring insulin production in type 1 diabetes.
- To explore alternatives to current therapies that address their inherent limitations.
Main Methods:
- Review of current and emerging therapeutic approaches for type 1 diabetes.
- Discussion of cell-based therapies, including xenotransplantation (porcine islets) and stem cell differentiation (embryonic and induced pluripotent stem cells).
- Exploration of gene-based strategies, such as ectopic gene expression and in vivo gene delivery for surrogate beta-cell generation.
Main Results:
- Multiple avenues are being investigated to restore insulin production, offering potential solutions beyond conventional treatments.
- Porcine islets, stem cell-derived beta-cells, and genetically engineered cells show promise in preclinical studies.
- In vivo gene therapy approaches are also under investigation for creating functional beta-cells.
Conclusions:
- Novel therapeutic strategies, including cell and gene therapies, hold significant promise for overcoming the limitations of current type 1 diabetes management.
- These approaches aim to restore physiological insulin secretion, potentially improving patient outcomes and reducing long-term complications.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...